Ost Investment
VC Fund
Ost Investment is a VC fund focused on Biotechnology and Health Care. Ost Investment
- Total investments:
- 5
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Ost Investment invests in
Stages Ost Investment invests in
Countries Ost Investment invests in
Round sizes
Round size
- Series A
- $1.3M–$2.7M
Investment Focus
Industry
- Biotechnology 4 (80%)
- Health Care 2 (40%)
- Life Science 2 (40%)
- Therapeutics 2 (40%)
- Food and Beverage 2 (40%)
Stage
- Series A 3 (60%)
- Seed 1 (20%)
- Funding Round 1 (20%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Bionetix Therapeutics is a developer of anticancer drugs designed for cancer treatment. The company's drugs include medicines for ophthalmic disease and glaucoma treatment, enabling patients to get early treatment for eye diseases, cancer and other diseases with unmet needs. | $3M / Seed / Dec 22, 2017 | ||
| Pinot Bio is a biotechnology company that specializes in developing new generation anticancer treatments. | $2.7M / Series A / Dec 07, 2017 | ||
| GFLAS Life Sciences, Inc. is poised to disrupt the agricultural biotechnology sector with its pioneering advancements in CRISPR-Cas genome editing technology. Founded by Dr. Sunghwa Choe in 2014, GFLAS has swiftly established itself as a leader in biotech innovation, dedicated to enhancing human health and promoting agricultural sustainabilitythrough cutting-edge genetic engineering solutions. Our flagship innovation, the world's first vitamin D3-enriched tomatoes, addresses a critical market need by transforming the traditional tomato industry. Tomatoes are one of the most consumed vegetables globally, with the US fresh tomato market alone valued at approximately $18 billion annually, assuming an average price of $1.5 per kilogram. The consumer market value is even more substantial, estimated between $27 to $31.5 billion annually. By introducing vitamin D3-enriched tomatoes, GFLAS not only adds significant nutritional value to a staple food product but also creates a unique selling proposition that meets the increasing consumer demand for functional foods. The strategic partnership with Bayer, a global leader in agricultural science, underscores the commercial viability and substantial market potential of our technology. This collaboration has facilitated the transfer of GFLAS's vitamin D3 tomato technology to Bayer Crio Science in the USA, providing a robust pathway for large-scale commercialization and global market penetration. This partnership not only validates our technological prowess but also positions us for significant growth in the global agricultural market. Our vitamin D3-enriched tomatoes offer numerous advantages over traditional vitamin D supplements. They provide a sustainable, plant-based source of vitamin D3, catering to vegans, vegetarians, and individuals with dietary restrictions or limited sun exposure. Unlike vitamin D3 derived from animal sources, our tomatoes are free from the risk of chemical contamination, making them a safer and more natural alternative. Furthermore, incorporating vitamin D3 into a widely consumed food product enhances consumer acceptance and adherence to recommended dietary intakes. The market potential for our innovations is immense. By capturing a significant share of the $18 billion US wholesale tomato market, our vitamin D3-enriched tomatoes can appeal to health-conscious consumers and address the needs of populations at risk of vitamin D deficiency. Additionally, our enhanced CRISPR-Cas technologies offer transformative possibilities across various agricultural applications, positioning GFLAS for sustained growth and profitability. We are now seeking investment to accelerate our expansion and capitalize on the lucrative opportunities within the US market and beyond. Our financial projections indicate substantial growth, with a target of achieving 30% market share within four years. The infusion of capital will support scaling up production, enhancing quality control, and expanding distribution and marketing efforts. GFLAS Life Sciences invites private equity funds and strategic investors to join us in this groundbreaking venture. With our cutting-edge technologies, strong partnerships, and clear market potential, GFLAS is uniquely positioned to deliver substantial returns on investment while making a profound positive impact on global health and sustainability. We look forward to discussing this exciting investment opportunity further and exploring how we can work together to bring our revolutionary products to market. | $1.9M / Series A / Feb 28, 2017 | ||
| Kitchen Doctor engages in research and development of diet programs for diabetes. Kitchen Doctor is based in Daejeon, South Korea with an additional office in Seoul, South Korea. | $1.3M / Series A / Sep 28, 2016 | ||
| See all 5 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does Ost Investment invest in?
Ost Investment invests primarily in Biotechnology, Health Care and Life Science startups, most often at Series A and Seed stage. Most of the 5 investments tracked by Shizune back companies in South Korea. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What round sizes does Ost Investment invest in?
Ost Investment typically joins rounds of $1.3M–$2.7M at Series A. These are whole funding-round sizes, not Ost Investment's own check, which is rarely disclosed: the 10th–90th percentile of the confirmed public funding rounds Ost Investment took part in.
When did Ost Investment last invest?
The most recent investment recorded for Ost Investment closed in Dec 2017. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Nov 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
